Your browser doesn't support javascript.
loading
Chest wall infiltration is a critical prognostic factor in breast implant-associated anaplastic large-cell lymphoma affected patients.
Campanale, Antonella; Di Napoli, Arianna; Ventimiglia, Marco; Pileri, Stefano; Minella, Daniela; Curigliano, Giuseppe; Martelli, Maurizio; De Vita, Roy; Di Giulio, Paola; Montorsi, Marco; Veronesi, Paolo; Giordano, Silvia; Iachino, Achille; Lispi, Lucia.
Afiliação
  • Campanale A; Directorate General of Medical Device and Pharmaceutical Service - Italian Ministry of Health, Rome, Italy; Group of Experts on BIA-ALCL at the Italian Ministry of Health, Italy.
  • Di Napoli A; Group of Experts on BIA-ALCL at the Italian Ministry of Health, Italy; Department of Clinical and Molecular Medicine, Sapienza University, Sant'Andrea Hospital, Rome, Italy.
  • Ventimiglia M; Directorate General of Medical Device and Pharmaceutical Service - Italian Ministry of Health, Rome, Italy.
  • Pileri S; Group of Experts on BIA-ALCL at the Italian Ministry of Health, Italy; Haematopathology Division, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Minella D; Directorate General of Medical Device and Pharmaceutical Service - Italian Ministry of Health, Rome, Italy.
  • Curigliano G; Group of Experts on BIA-ALCL at the Italian Ministry of Health, Italy; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy. Electronic address: giuseppe.c
  • Martelli M; Group of Experts on BIA-ALCL at the Italian Ministry of Health, Italy; Department of Translational and Precision Medicine "Sapienza" University, Rome, Italy.
  • De Vita R; Group of Experts on BIA-ALCL at the Italian Ministry of Health, Italy; Plastic Surgery Department, National Institute for Cancer, Rome, Italy.
  • Di Giulio P; Group of Experts on BIA-ALCL at the Italian Ministry of Health, Italy; Department of Public Health and Paediatrics, Turin University, Italy.
  • Montorsi M; Group of Experts on BIA-ALCL at the Italian Ministry of Health, Italy; Humanitas University and Humanitas Research Center, IRCCS, Milan, Italy.
  • Veronesi P; Group of Experts on BIA-ALCL at the Italian Ministry of Health, Italy; Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy; Division of Breast Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Giordano S; Group of Experts on BIA-ALCL at the Italian Ministry of Health, Italy; Department of Oncology, University of Torino and Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
  • Iachino A; Directorate General of Medical Device and Pharmaceutical Service - Italian Ministry of Health, Rome, Italy; Group of Experts on BIA-ALCL at the Italian Ministry of Health, Italy.
  • Lispi L; Directorate General of Medical Device and Pharmaceutical Service - Italian Ministry of Health, Rome, Italy; Group of Experts on BIA-ALCL at the Italian Ministry of Health, Italy.
Eur J Cancer ; 148: 277-286, 2021 05.
Article em En | MEDLINE | ID: mdl-33765512
ABSTRACT

BACKGROUND:

Breast implant-associated anaplastic large-cell lymphoma is a rare disease with a favourable prognosis if adequately treated. Same staged patients have usually a similar prognosis and outcomes, but in our experience, IIA-staged patients have a wider prognosis with outcomes that vary from complete disease response to death. This study aimed to understand and identify all the factors that could influence the prognosis of this group of patients and verify if their prognosis matches the stage they belong to. MATERIAL AND

METHODS:

Patients in stage IIA have been divided into two subgroups IIAb with lymphoma extension towards the glandular tissue and IIAcw with tumour extension towards the chest-wall. The overall survival (OS) and event-free survival (EFS) of 64 BIA-ALCL cases were evaluated for each staged group.

RESULTS:

Significant differences of OS and EFS between IIAb and IIAcw patients (log-rank p = 0.046 and log-rank p = 0.018, respectively) were observed and poor prognosis joined IIAcw- and IV-staged patients.

CONCLUSION:

Chest-wall infiltration is a critical prognostic factor in BIA-ALCL patients as it influences the possibility of performing a surgical radical tumour extirpation. Our results could represent valid assistance for the physicians in choosing the most appropriate BIA-ALCL prognostic category and treatment and could promote further wider studies to provide stronger evidence on a possible revision of the MDA TNM classification.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Linfoma Anaplásico de Células Grandes / Implantes de Mama / Parede Torácica Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Linfoma Anaplásico de Células Grandes / Implantes de Mama / Parede Torácica Idioma: En Ano de publicação: 2021 Tipo de documento: Article